By Dr Mark Theo Bloch

Journal articles

Kinloch-De Loes S; Hoen B; Smith DE; Autran B; Lampe FC; Phillips AN; Goh LE; Andersson J; Tsoukas C; Sonnerborg A; Tambussi G; Girard PM; Bloch M; Battegay M; Carter N; El Habib R; Theofan G; Cooper DA; Perrin L, 2005, 'Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection', Journal of Infectious Diseases, 192, pp. 607 - 617, http://dx.doi.org/10.1086/432002

Chee CC; Mortier E; Dupont C; Bloch M; Simonpoli AM; Rouveix E, 2005, 'Medical and social differences between French and migrant patients consulting for the first time for HIV infection', AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 17, pp. 516 - 520, http://dx.doi.org/10.1080/09540120412331291760

Winston A; Bloch MT; Carr AD; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S, 2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, 56, pp. 380 - 387

Ray J; Marriott D; Bloch MT; McLachlan AJ, 2005, 'Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic', British Journal of Clinical Pharmacology, 60, pp. 291 - 299

Van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJP; Schechter M; Murphy RL; Horban A; Hall DB; Lange JMA; Reiss P, 2004, 'Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1', PLoS Medicine, 1, pp. 064 - 074, http://dx.doi.org/10.1371/journal.pmed.0010019

Martin A; Smith DE; Carr AD; Hoy JF; Chuah J; Mallal SA; Law MG; Clements MS; Cooper DA, 2004, 'Progression of lipodystrophy (LD) with continued thymidine analogue usage: Long-term follow-up from a randomized clinical trial (the PIILR study)', HIV Clinical Trials, 5, pp. 192 - 200, http://thomasland.metapress.com/content/0gu76x27mmhe5ale/

Mortier E; Toure S; Seyler C; Bloch M; Anglaret X, 2003, 'Urinary pH in HIV-infected adults in Ivory Coast and in France [3]', AIDS, 17, pp. 2003 - 2005, http://dx.doi.org/10.1097/00002030-200309050-00028

Levy Y; Durier C; Krzysiek R; Rabian C; Capitant C; Lascaux AS; Michon C; Oksenhendler E; Weiss L; Gastaut JA; Goujard C; Rouzioux C; Maral J; Delfraissy JF; Emilie D; Aboulker JP; Gougeon ML; Metro A; Viard JP; Bouchenafa K; Jung C; Mortier E; Bloch M; Chandemerle C; Gérard L; Martinie M; Kazatchkine M; Laureillard D; Dinh TT; Dalmas AM; Peretti D; Rannou MT; Bazin C; Verdon R; Six M; Goubin P; Vittecoq D; Escaut L; Malet M; Maignan A; Bouvet E; Prevot MH; Fournier I; Gaudebout C; Yéni P; Belarbi L; Mandet C; Zucman D; Majerholc C; Boue F; Estocq GA; Delavalle AM; Pasquali JL; Lalanne H; Bouchet-Delbos L; Chambenoit C; Carmagnat MV; Grangeot-Keros L; Ameisen JC; Estaquier J; Monnier D; Ferchal F; Girard PM; Laplanche A; Bazin B; Foubert V; Izard S; Martins J; Netzer E, 2003, 'Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: A randomized controlled trial', AIDS, 17, pp. 343 - 351, http://dx.doi.org/10.1097/00002030-200302140-00008

Kaufmann GR; Bloch MT; Finlayson RJ; Zaunders J; Smith DE; Cooper DA, 2002, 'The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy', AIDS, 16, pp. 359 - 367

Bloch M, 2001, 'Current tren HIV therapy', Current Therapeutics, 42, pp. 8 - 12

Bodsworth NJ; Bloch M; Bower M; Donnell D; Yocum R; International Panretin Gel KS Study Group , 2001, 'Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma.', Am J Clin Dermatol, 2, pp. 77 - 87, http://dx.doi.org/10.2165/00128071-200102020-00004

Stewart GA; Ashton LJ; Biti RA; Ffrench FA; Bennetts BH; Newcombe NR; Benson EM; Carr AD; Cooper DA; Kaldor JM; Smith DD; Catchpole BR; Allworth A; Baker D; Batty G; Beveridge A; Bloch M; Bodsworth NJ; Clare K; Cummins E; Cunningham PH; Couldwell D; Deacon N; Doong N; Finlayson R; Furner V; Huffam SE; Kidd J; Kelly MD; Lloyd AR; Mcfarlane R; Mclean K; Mcnulty A; Mcphee D; Michelmore H; Mcmurchie M; Mutimer K; Peterson J; Price R; Quan J; Qurn J; Ree H; Robertson M; Roggensack M; Schroeder K; Spencer D; Sullivan JS; Ziegler JB, 1997, 'Increased frequency of CCR-5 delta32 heterozygotes among long-term nonprogressors with HIV infection.', AIDS, 11, pp. 1833 - 1838

Bloch MW; Smith DA; Nelson DL, 1989, 'Heart rate, activity, duration, and affect in added-purpose versus single-purpose jumping activities.', The American journal of occupational therapy. : official publication of the American Occupational Therapy Association, 43, pp. 25 - 30, http://dx.doi.org/10.5014/ajot.43.1.25

Conference Papers

Cahn P; Sax PE; Squires K; Molina JM; Ratanasuwan W; Rassool M; Bloch M; Xu X; Zhou Y; Homony B; Hepler D; Teppler H; Hanna GJ; Nguyen BY; Greaves W, 2018, 'Raltegravir 1200 mg once daily vs 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 infection: Week 96 results from ONCEMRK, a randomized, double-blind, noninferiority trial', in Journal of Acquired Immune Deficiency Syndromes, pp. 589 - 598, http://dx.doi.org/10.1097/QAI.0000000000001723

Siefried KJ; Mao L; Cysique LA; Rule J; Giles ML; Smith DE; McMahon J; Read TR; Ooi C; Tee BK; Bloch M; de Wit J; Carr A, 2017, 'Polypharmacy of concomitant medications in HIV-infected Australian adults is common, and associated with adverse effects', in Antiviral Therapy, International Medical Press, Milan, Italy, presented at The 19th International Workshop on Co-morbidities and Adverse Drug Reaction in HIV, Milan, Italy, 23 October 2017 - 25 October 2017, http://dx.doi.org/10.26190/unsworks/27403

Connor D; Greaves I; Porter K; Bloch M, 2013, '1067-1069 Pre-hospital spinal immobilisation: An initial consensus statement', in Emergency Medicine Journal, pp. 1067 - 1069, http://dx.doi.org/10.1136/emermed-2013-203207

Scott I; Porter K; Laird C; Greaves I; Bloch M, 2013, 'The prehospital management of pelvic fractures: Initial consensus statement', in Emergency Medicine Journal, pp. 1070 - 1072, http://dx.doi.org/10.1136/emermed-2013-203211

Bloch M; Martin A; Amin I; Emery S; Carr A; Baker D; Cooper DA, 2010, 'Predictors of limb fat changes in patients switched to tenofovir-emtricitabine or abacavir-lamivudine', in ANTIVIRAL THERAPY, INT MEDICAL PRESS LTD, ENGLAND, London, pp. A7 - A7, presented at 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, ENGLAND, London, 04 November 2010 - 06 November 2010, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000287431500008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Michon C; Facy F; Boue F; Henry S; Bloch M, 1993, 'Evaluation of the medical follow-up in drug addicts with HIV infection. Report and preliminary results of a multicentric study in Ile-de-France', in Revue d'Epidemiologie et de Sante Publique

Conference Posters

Siefried KJ; Mao L; Cysique LA; Rule J; Giles ML; Smith DE; McMahon J; Read TR; Ooi C; Tee BK; Bloch M; de Wit J; Carr A, 2017, 'Polypharmacy of concomitant medications in HIV-infected Australian adults is common, and associated with adverse effects', Milan, Italy, presented at The 16th European AIDS Conference, Milan, Italy, 25 October 2017 - 27 October 2017

Conference Presentations

Siefried KJ; Mao L; Cysique LA; Rule J; Giles ML; Smith DE; McMahon J; Read TR; Ooi C; Tee BK; Bloch M; de wit J; Carr A, 2017, 'Polypharmacy of concomitant medications in HIV-infected Australian adults is common, and associated with adverse effects', presented at The Australasian HIV&AIDS Conference, Canberra Australia, 06 November 2017 - 08 November 2017

Conference Abstracts

Martinello M; Bartlett S; Dore G; Bopage R; Finlayson R; Baker D; Bloch M; Doyle J; Shaw D; Hajkowicz K; Read P; Filep E; Lin L; Yee J; Applegate T; Hellard M; Matthews G, 2018, 'Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia', in Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia, Paris, France, presented at THE INTERNATIONAL LIVER CONGRESS 2018, Paris, France, 11 April 2018 - 15 April 2018

Martinello M; Dore GJ; Bopage RI; Finlayson R; Baker D; Bloch M; Wilcox A; Filep E; Hellard M; Matthews GV, 2017, 'DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S495 - S496, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31388-0

Preprints

Dawson M; Dharan N; Yeh P; Bloch M; Yeung M; Baker D; Guinto J; Roth N; Ftouni S; Ognenovska K; Smith D; Hoy J; Woolley I; Pell C; Templeton D; Fraser N; Rose N; Hutchinson J; Petoumenos K; Dawson S-J; Polizzotto M, 2020, Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study, http://dx.doi.org/10.21203/rs.3.rs-106576/v1

Dharan N; Yeh P; Bloch M; Yeung M; Baker D; Guinto J; Roth N; Ftouni S; Ognenovska K; Smith D; Hoy J; Woolley I; Pell C; Templeton D; Fraser N; Rose N; Hutchinson J; Petoumenos K; Dawson S-J; Polizzotto M; Dawson M; for the ARCHIVE Study Group , 2020, Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study, http://dx.doi.org/10.1101/2020.11.19.20235069

Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Rowling D; Doong N; Jackson E; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study, http://dx.doi.org/10.2139/ssrn.3269607

Back to profile page